Relationship between myocarditis and infection caused by SARS-CoV-2
DOI:
https://doi.org/10.33448/rsd-v10i7.16357Keywords:
Myocarditis; Health; New coronavirus.Abstract
Based on data from China, where the pandemic originated, cardiac injury has become a prominent feature of the disease, affecting up to 30% of patients and helping 40% of deaths. Several cardiovascular complications have been described, such as myocardial injury (20% of cases), arrhythmias (16%), myocarditis (10%), in addition to heart failure (HF) and shock (up to 5% of cases). The aim of this work is to inform and describe the new myocarditis caused by the new virus. And demonstrate the importance for further studies related to the new disease. All publications that have data on the new myocarditis in patients with the new SARS-CoV-2, scientific publications, official from the World Health Organization and government, between a certain date (2019-2021) were used. Approximately 500 articles were found, languages were checked, and if it was really about the theme of the new myocarditis related to the new virus, then 39 articles were obtained for the discussion. Myocardial injury, signaled by markers, was evidenced in the first cases of the disease. The National Health Council of China demonstrated in a report, 12% of patients without cardiovascular problems. Thus, since SARS-CoV-1 and SARS-CoV-2 reach cells through the angiotensin-converting enzyme 2, where this possibly also happens in patients infected with the new virus. However, more research is still needed to prove these possible theories.
References
Alves, V. S., Nunes, M. O. (2006). Educação em saúde na atenção médica ao paciente com hipertensão arterial no Programa Saúde da Família. Interface Comum. Saúde Educ; 10(19):131-147.
Araújo, J. C., Guimarães, A. C. (2007). Controle da Hipertensão. Arterial em uma Unidade de Saúde da Família. Rev. Saúde Pública; 41(3):368-374.
Brasil. (2020). Segundo Posicionamento do Departamento de Hipertensão Arterial da Sociedade Brasileira de Cardiologia (DHA/SBC) sobre inibidores da enzima de conversão da angiotensina (IECA), bloqueadores dos receptores da angiotensina (BRA) e Coronavírus (COVID-19).
Carnelosso, M. L. C. (2008). Iniciativa Carment: resultados e tendências das prevalências dos fatores de risco cardiovasculares [tese]. Goiânia (GO): Programa Multi-institucional de Pós-Graduação em Ciências da Saúde, Convênio Centro Oeste/Universidade de Brasília (UNB), Universidade Federal de Goiás (UFG), Universidade Federal de Mato Grosso do Sul (UFMS).
Costa, I. B. S. S., Bittar, C. S., Rizk, S. I., Araújo Filho, A. E, Santos, K. A. Q., Machado, T. I. V., et al. (2020). The heart and COVID-19: what cardiologists need to know. Arq Bras Cardiol.
Colson, P., Rolain, J. M., Raoult, D. (2020). Chloroquine for the 2019 novel coronavirus SARS-CoV-2. International Journal of Antimicrobial Agents; 55(3).
Fang, L., Karakiulakis, G., Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med; 8(21).
Guan, W. J., Liang, W. H., Zhao, Y., et al. (2020). China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler T., Erichsen, S., et al. (2020). SARS- CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell; 181(2):271-80.
Kauark, F. (2010). Metodologia da pesquisa: guia prático / Fabiana Kauark, Fernanda Castro Manhães e Carlos Henrique Medeiros. – Ita- buna: Via Litterarum editora, 88p.
Kim, Y., Kwon, O., Paek, J. H., et al. (2020). Two distinct cases with COVID-19 in kidney transplant recipients. American journal of transplantatio: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
Marães, V. R., Silva, E., Catai, A.M., Novais, L.D., Moura, M.S., Oliveira, L., et al. (2005). Identification of anaerobic threshold using heart rate response during dynamic exercise. Braz J Med Biol Res; 38(5):731-5.
Million, M. (2020). Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel medicine and infectious disease.
Patel, A. B., Verma, A. (2020). COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angio¬tensin Receptor Blockers: What Is the Evidence?. JAMA.
Pearson, T. A., Walls, S., Lewis, C. (2001). Dissecting the ‘‘black box’’ of community intervention: lessons from community- wide cardiovascular disease prevention programs in the US and Sweden. Scand J Public Health; 29(56):69-78.
Qiao, Y., Shin, J. I., Chen, T. K., et al. (2020). Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med.
Sarayani, A., Cicali, B., Henriksen, C. H., Brown, J. D. (2020). Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Research in social & administrative pharmacy: RSAP.
Turner, A. J., Hiscox, J. A., Hooper, N. M. (2004). ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol; 25(6):291-4.
Vaduganathan, M., Vardeny, O., Michel, T., et al. (2020). Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19. N Engl J Med.
Wan, Y., Shang, J., Graham, R., et al. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol; 94.
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W. (2020) Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv.
Zheng. Y. Y., Ma, Y. T, Zhang, J. Y., Xie, X. (2020). COVID-19 and the cardiovascular system. Nat Rev Cardiol.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 José Chagas Pinheiro Neto; Higo José Neri da Silva; Juliana Vanessa Cavalcante Souza; Karene Ferreira Cavalcante; Denys Wanderson Pereira Frazão; Alexandre Mendes Soares; Ana Carolina Hortencio Garcia ; Danilo do Nascimento Viana; Camila dos Santos Xavier; Denis Romulo Leite Furtado; Lizandro de Freitas Pessoa; Márcia Laís Fortes Rodrigues Mattos; Manoel Lopes da Silva Filho; Manuelle Rodrigues da Silva; Kelly Maria Rêgo da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
